VIVS

Insider Trades

Name	Value	Action	Price	Current Price
Gobel DavidDirector $7.3k3.3k shares SellNov 17, 2025 $2.24 --

News

globenewswire.comVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testingglobenewswire.comApr 28

defenseworld.netShort Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%defenseworld.netApr 27

globenewswire.comVivoSim Announces Pricing of up to a $4 Million Public Offeringglobenewswire.comApr 1

defenseworld.netHead-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)defenseworld.netMar 27

globenewswire.comVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsglobenewswire.comMar 24

Trade VIVS

About VivoSim Labs, Inc.

VivoSim Labs, Inc. is a biotechnology company dedicated to developing sophisticated 3D tissue models designed to replicate key aspects of human diseases. At the heart of their operations is a proprietary 3D human tissue platform, which incorporates their advanced NovoGen Bioprinters. These automated devices are engineered to construct intricate 3D living tissues using mammalian cells, alongside complementary technologies vital for preparing specialized bio-inks and for the precise bioprinting of multi-cellular tissues with complex architectural designs. The company's leading therapeutic prospect, FXR314, is currently undergoing a Phase 2/3 clinical trial for inflammatory bowel disease, with a specific focus on ulcerative colitis. Furthermore, FXR314 has successfully completed a Phase 1 clinical trial investigating its efficacy for liver fibrosis, particularly steatohepatitis. VivoSim Labs maintains active research collaborations concerning its NovoGen Bioprinters with prestigious institutions such as the Yale School of Medicine, the Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia. Established in 2007 and headquartered in San Diego, California, the company previously operated under the name Organovo Holdings, Inc. before officially rebranding to VivoSim Labs, Inc. in April 2025.

CEO: Keith E. Murphy
IPO Date: Feb 14, 2012

Market Data

Open: $1.15
High: $1.18
Low: $1.10
Volume: 87.5K
Avg Volume: 73.3K
52W High: $5.30
52W Low: $1.10

Valuation

Market Cap: $2.9M
Enterprise Value: $-842k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-9.5M
Revenue: $144k
Net Income: $-2.5M
Cash: $11M
Debt: $942k

Events

EarningsAug 6